Skip to content

D&A at other companies

IAR
Integra LifeSciencesIART
$38.43M+3.3%
Bioventus logo
BioventusBVS
$11.21M-5.6%
Artivion logo
ArtivionAORT
$6.34M+16.4%
Axogen logo
AxogenAXGN
$1.6M-7.2%
LeMaitre Vascular logo
LeMaitre VascularLMAT
$2.62M+2.8%
Vericel logo
VericelVCEL
$3.27M+21.6%

Other financials

Income statement

See full
Revenue$37.2M-57.1%
Gross profit$63.0M-22.5%
Operating income-$68.9M-158%
Net income-$53.2M-182%
EPS (diluted)-$0.44-159%

Balance sheet

See full
Cash & equivalents$91.4M-16.9%
Total debt$39.4M+24.8%
Total equity$244.6M+0.7%
Total assets$520.0M+11.3%

Cash flow

See full
Operating cash flow$21.1M+206%
CapEx$3.1M-13.2%
Free cash flow$18.0M+176%

Valuation

See full
Market cap$312.68M-23.7%
Enterprise value$260.72M-21.3%
P/E115×
P/S0.6×-0.3×

Profitability

See full
Gross margin75.9%+0.8pp
Operating margin0.5%
Net margin0.5%+0.3pp
FCF margin6.9%

Returns & leverage

See full
Return on equity1.1%+0.6pp
Debt / equity0.2×0.0×
Current ratio3.5×-0.6×

Where this comes from

Reported directly by Organogenesis Holdings Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Organogenesis Holdings Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organogenesis Holdings Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organogenesis Holdings Inc.'s D&A?
Organogenesis Holdings Inc. (ORGO) reported D&A of $4.17M in Q1 2026.
How has Organogenesis Holdings Inc.'s D&A changed year-over-year?
Organogenesis Holdings Inc.'s D&A increased by 21.2% year-over-year, from $3.44M to $4.17M.
What is the long-term trend for Organogenesis Holdings Inc.'s D&A?
Over 4 years (2021 to 2025), Organogenesis Holdings Inc.'s D&A has grown at a 27.5% compound annual growth rate (CAGR), from $5.78M to $15.27M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.